Connor, Clark & Lunn Investment Management Ltd.

Position in GH — Guardant Health, Inc.

CIK 1596800 VANCOUVER, A1

Position in GH

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$32,315,711

+$8,780,944 QoQ

Shares Held

215,395

-15.5% QoQ

Ownership

0.161%

of shares outstanding

% of Portfolio

0.06%

of 13F equity value

Holder Rank

#89

of 594 holders

Holding Since

Mar 2021

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $189,818,037 across 16 Diagnostics & Research names. GH ranks #2 (17.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	MEDP	Medpace Holdings, Inc.	110,353	$58,441,845
2	GH	Guardant Health, Inc. This page	215,395	$32,315,711
3	DHR	Danaher Corp /De/	114,010	$21,716,624
4	TMO	Thermo Fisher Scientific Inc.	36,269	$18,183,825
5	NEO	Neogenomics Inc	802,597	$11,709,889
6	RVTY	Revvity, Inc.	87,145	$9,695,752
7	MYGN	Myriad Genetics Inc	1,407,860	$8,038,880
8	CSTL	Castle Biosciences Inc	331,727	$7,911,688

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$32,315,711	215,395	-15.5%	Shares	Sole	2026-08-13
2026-03-31	$23,534,767	254,788	-4.4%	Shares	Sole	2026-05-11
2025-12-31	$27,219,492	266,492	+83.3%	Shares	Sole	2026-02-10
2025-09-30	$9,082,092	145,360	+1164.8%	Shares	Sole	2025-11-13
2023-06-30	$411,449	11,493	-92.9%	Shares	Sole	2023-08-10
2023-03-31	$3,804,616	162,313	+860.5%	Shares	Sole	2023-05-10
2022-12-31	$459,625	16,898	+420.1%	Shares	Sole	2023-02-10
2021-09-30	$406,157	3,249	-89.0%	Shares	Sole	2021-11-12
2021-06-30	$3,678,756	29,622	+364.9%	Shares	Sole	2021-08-12
2021-03-31	$972,685	6,372	—	Shares	Sole	2021-05-13
No filing history on record for this holder in this stock.